| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.098 | 0.07 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.053 | 0.07 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.08 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.097 | 0.08 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |